Biotech Values

[DewDiligence]

New meta-analysis shows Xience is even better than people thought:

http://www.forbes.com/sites/larryhusten/2012/03/22/large-meta-analysis-finds-very-low-thrombosis-rates-for-xience-stent

A large new meta-analysis published in the Lancet provides the best evidence yet that the cobalt-chromium everolimus eluting (CoCr-EES) stents (Xience and Promus) have a significantly lower rate of stent thrombosis than bare-metal stents and other drug-eluting stents. Tullio Palmerini and colleagues analyzed data from 49 randomized trials comparing different stents in more than 50,000 patients.

This was reported at ACC; chase the link above to see the hazard ratios for various metrics.

These data probably won’t make much difference commercially because Xience was already the market leader among DES’s by a wide margin; however, the meta-analysis might conceivably influence some bare-metal proponents.